16-23635732-C-T
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_024675.4(PALB2):c.814G>A(p.Glu272Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000161 in 1,613,994 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E272G) has been classified as Uncertain significance.
Frequency
Consequence
NM_024675.4 missense
Scores
Clinical Significance
Conservation
Publications
- hereditary breast carcinomaInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen, Ambry Genetics
- Fanconi anemia complementation group NInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- pancreatic cancer, susceptibility to, 3Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- familial ovarian cancerInheritance: AD Classification: MODERATE Submitted by: ClinGen
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| PALB2 | NM_024675.4 | c.814G>A | p.Glu272Lys | missense_variant | Exon 4 of 13 | ENST00000261584.9 | NP_078951.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| PALB2 | ENST00000261584.9 | c.814G>A | p.Glu272Lys | missense_variant | Exon 4 of 13 | 1 | NM_024675.4 | ENSP00000261584.4 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152140Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000239 AC: 6AN: 251414 AF XY: 0.0000294 show subpopulations
GnomAD4 exome AF: 0.0000164 AC: 24AN: 1461854Hom.: 0 Cov.: 32 AF XY: 0.0000193 AC XY: 14AN XY: 727228 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152140Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74310 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Familial cancer of breast Uncertain:3Benign:1
- -
Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitter to LOVD: Marc Tischkowitz. -
This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 272 of the PALB2 protein (p.Glu272Lys). This variant is present in population databases (rs515726127, gnomAD 0.02%). This missense change has been observed in individual(s) with breast and/or ovarian cancer (PMID: 21356067, 34284872). ClinVar contains an entry for this variant (Variation ID: 126772). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The lysine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
This variant is considered benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. Homozygosity for this variant has been confirmed in one or more individuals lacking clinical features consistent with gene-specific recessive disease, indicating that this variant is unlikely to be pathogenic. -
Hereditary cancer-predisposing syndrome Uncertain:3
The p.E272K variant (also known as c.814G>A), located in coding exon 4 of the PALB2 gene, results from a G to A substitution at nucleotide position 814. The glutamic acid at codon 272 is replaced by lysine, an amino acid with similar properties. This variant has been reported in the literature in cohorts of Finnish and Spanish breast cancer patients (Kuusisto KM et al. Breast Cancer Res. 2011 Feb;13:R20; Velázquez C et al. Breast. 2019 Feb;43:91-96). This variant was reported in 3/60,466 breast cancer cases and in 2/53,461 controls (Dorling et al. N Engl J Med. 2021 02;384:428-439). This variant was also detected in a cohort of 1280 consecutive cancer patients with breast and/or ovarian cancer (HBOC) (Butz H et al. Cancers (Basel), 2023 Aug;15). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
BP1 c.814G>A, located in exon 4 of the PALB2 gene, is predicted to result in the substitution of glutamic acid by lysine at codon 272, p.(Glu272Lys). The SpliceAI algorithm predicts no significant impact on splicing and there is a very low likelihood that missense variants are pathogenic in PALB2 (BP1). This variant is found in 7/268282 alleles at a frequency of 0.0026% in the gnomAD v2.1.1 database, non-cancer dataset. To our knowledge, neither relevant clinical data nor well-stablished functional studies have been reported for this variant. It has been reported in the ClinVar database (8x uncertain significance) and in the LOVD database (2x likely benign, 2x uncertain significance). Based on the currently available information, c.814G>A is classified as an uncertain significance variant according to ClinGen-PALB2 Guidelines version v1.0.0. -
This missense variant replaces glutamic acid with lysine at codon 272 of the PALB2 protein. Computational prediction suggests that this variant may not impact protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in at least three individuals affected with breast and/or ovarian cancer (PMID: 21356067, 30521987, 37686625, 38061684), and it has been detected in a breast cancer case-control meta-analysis in 3/60466 cases and 2/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID PALB2_010049). This variant has been identified in 7/282818 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
not provided Uncertain:2
The PALB2 c.814G>A (p.Glu272Lys) variant has been reported in the published literature in individuals with breast and/or ovarian cancer (PMIDs: 21356067 (2011), 30521987 (2019), 33471991 (2021), 37686625 (2023)), and in reportedly healthy individuals (PMID: 33471991 (2021)). The frequency of this variant in the general population, 0.00012 (3/25118 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 21356067, 33471991, 19369211, 34284872, 30521987, 37686625, 38061684, Tuncer2023[CaseReport]) -
not specified Uncertain:1
- -
Familial cancer of breast;C1835817:Fanconi anemia complementation group N;C3150547:Pancreatic cancer, susceptibility to, 3 Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at